Thu, October 6, 2016
Wed, October 5, 2016

Paul Matteis Downgraded (ALNY) to Hold and Decreased Target to $40 on, Oct 6th, 2016

Paul Matteis of Leerink Swann, Downgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Hold and Decreased Target from $107 to $40 on, Oct 6th, 2016.

Paul has made no other calls on ALNY in the last 4 months.



There is 1 other peer that has a rating on ALNY. Out of the 1 peers that are also analyzing ALNY, 0 agree with Paul's Rating of Hold.



This is the rating of the analyst that currently disagrees with Paul


  • Anupam Rama of "JP Morgan" Maintained at Buy with Increased Target to $83 on, Friday, August 5th, 2016